Skip to text

Buy one 50ml, get one 15ml for free

Subscribe to our newsletter and get 10% off!

Buy one 100ml, get 2x 15ml for free

  • For eczema
  • For rosacea
  • For acne
  • Product sets
  • The brand

  • Reviews
  • Our Advanced Technology
  • Facebook
  • Twitter
  • Instagram
  • YouTube
Navigation
  • For eczema
  • For rosacea
  • For acne
  • Product sets
  • The brand
  • Reviews
  • Our Advanced Technology
Open cart drawer
0
Successful Treatment of Chronic Staphylococcus aureus-Related Dermatoses with theTopical Endolysin Staphefekt SA.100: A Report of 3 Cases

Successful Treatment of Chronic Staphylococcus aureus-Related Dermatoses with theTopical Endolysin Staphefekt SA.100: A Report of 3 Cases

This publication describes 3 cases where patients with chronic and recurrent S. aureus-related dermatoses were successfully treated with Staphefekt SA.100, the active ingredient of Gladskin. The results indicate that targeted...

19 September 2017
Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis

Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis

This study shows that the skin-microbiome in patients with eczema/atopic dermatitis is characterized by overgrowth of S. aureus bacteria. More overgrowth was linked to more severe symptoms. On the other hand a...

20 June 2017
Staphefekt – intervening early in the Colonisation Infection Continuum with endolysins

Staphefekt – intervening early in the Colonisation Infection Continuum with endolysins

With Staphefekt, the first targeted therapy against S. aureus is available for long-term daily maintenance therapy, aimed at decreasing the burden of skin colonisation and preventing progression to inflammation and...

20 June 2016
Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis

Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis

These results demonstrate the importance of colonization with S. aureus in Atopic Dermatitis... At present, new targeted antimicrobial therapies (such as lysins) are being developed, which are directed against single...

20 June 2016
Staphefekt is featured in The Biomedical Scientist as being the first effective alternative to antibiotics for suppression of S. aureus on the skin.

Staphefekt is featured in The Biomedical Scientist as being the first effective alternative to antibiotics for suppression of S. aureus on the skin.

The endolysin Staphefekt is the active ingredient of Gladskin products and it could play a big role in the maintenance treatment of chronic skin conditions where bacteria are thought to...

23 October 2015
New study suggests S. aureus and skin dysbioses cause eczema

New study suggests S. aureus and skin dysbioses cause eczema

A mouse model for atopic dermatitis shows that changes in the skin microbiome corresponded with the disease state. It appears that S. aureus is a major culprit in causing eczema,...

29 April 2015
Scientists Develop Alternative To Antibiotics

Scientists Develop Alternative To Antibiotics

Staphefekt™ targets the unwanted antibiotic resistant Staphylococcus aureus-bacteria and leaves the essential bacteria intact. This bacteria causes or worsens the majority of all skin infections. Read the article on Sky News

06 November 2014

Newsletter

Get 10% off on your first order!

FREE SHIPPING FROM 45€ order

Secure payments with certified payment service providers

Contact us via live chat

10% discount when subscribing to our newsletter

  • REVIEWS
  • TERMS OF SALE
  • ABOUT US
  • CONTACT US
  • Blog
  • MEDIA
  • FAQ
  • PRIVACY POLICY
  • COOKIE SETTINGS
  • MY ACCOUNT
  • MY ORDERS
  • MY ADRESSES
  • SHOPPING CART
  • For Eczema
  • For Rosacea
  • For Acne
  • EU
    EU
  • NL
    NL
  • FR
    FR
  • UK
    UK
  • SE
    SE
  • DE
    DE
  • Facebook
  • Twitter
  • Instagram
  • YouTube
Payment methods

🇪🇺 “This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 873591”. © 2022, Gladskin EU

  • Refresh page